Home » Newsletters » BioWorld Science

BioWorld Science

May 3, 2016

View Archived Issues

Phase I results on IONIS-DMPK-2.5R for the treatment of myotonic dystrophy type 1

Celgene announces product highlights of first quarter 2016

Novel gemcitabine prodrug shows improved antitumor efficacy

Further trials planned after phase Ia study of cyclopropavir in healthy subjects

Arenavirus entry inhibitor from Kineta shows preclinical efficacy

CHMP recommends E.U. approval of Gazyvaro for treatment of previously treated follicular lymphoma

Novel anti-CD352 ADC SGN-CD352A

Positive topline results from phase II/III trial of fasinumab in patients with osteoarthritis pain

EMA's CHMP recommends approval of HyQvia in pediatric patients

FDA clears TRACT Therapeutics's phase II study of Treg therapy for kidney transplant rejection

Tobira Therapeutics interim results from ORION study of cenicriviroc

AstraZeneca completes acquisition of Takeda's core respiratory business

FDA awards new orphan drug designations to Kite Pharma's KTE-C19

Prosetta Biosciences enters agreement with Takeda to develop drugs for CNS disorders

Kamada receives two milestone payments from AAT agreements

Oncodesign enters into strategic partnership with Ipsen in oncology

Celsion reports data from OVATION study of GEN-1

Enrollment to continue in Protalex's phase Ib study of PRTX-100

EMA committee recommends approval of Ongentys

Progenics Pharmaceuticals licenses technology to Bayer

Encore Vision's phase I-II study of EV-06 meets primary endpoints

Rigel identifies MerTK inhibitors for treating cancer

FDA approves Eisai's Fycompa CIII oral suspension

Update on Acorda's acquisition of Biotie

Oligomerix receives a grant for its Alzheimer's drug discovery program from the NIH